Biostar Pharmaceuticals (Biostar Pharmaceuticals) Growth Rank : 0 (As of Apr. 29, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Biostar Pharmaceuticals Growth Rank?

Biostar Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Biostar Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Biostar Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Biostar Pharmaceuticals (Biostar Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biostar Pharmaceuticals Inc (OTCPK:BSPM) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 588 Shiji Xi Avenue, Shaanxi Province, Xianyang, CHN, 712046

Website

http://www.biostarpharmaceuticals.com

Biostar Pharmaceuticals Inc through its subsidiaries involves in the development, manufacturing, and marketing of pharmaceutical products for a variety of diseases and conditions in the People's Republic of China where it generates most of its revenues. The company's products include Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (OTC) medicine for chronic hepatitis B. The current product line of the company also includes several other OTC products and approximately 15 prescription-based pharmaceuticals. Its products are derived from medicinal herbs that are either grown at its own facility or purchased from the suppliers.

Biostar Pharmaceuticals (Biostar Pharmaceuticals) Headlines

From GuruFocus

Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice

By PRNewswire PRNewswire • 04-23-2018

Biostar Pharmaceuticals Announces Receipt of Additional Delisting Determination Letter from Nasdaq

By Marketwired Marketwired • 08-23-2018